Gilead questions 世界保健機構 熟考する／考慮する that cast 疑問s on 麻薬's COVID-19 利益s
By Deena Beasley and Vishwadha Chander
Oct 15 (Reuters) - Gilead Sciences Inc has questioned the findings of a World Health Organization (世界保健機構) 熟考する／考慮する that 結論するd its COVID-19 麻薬 remdesivir does not help 患者s who have been 認める to hospital.
The American company told Reuters the data appeared inconsistent, the findings were premature and that other 熟考する／考慮するs had 実証するd the 麻薬's 利益s.
In a blow to one of the few 麻薬s 存在 used to 扱う／治療する people with COVID-19, the 世界保健機構 said on Thursday its "団結" 裁判，公判 had 結論するd that remdesivir appeared to have little or no 影響 on 28-day mortality or length of hospital stays の中で 患者s with the respiratory 病気.
The antiviral 医薬 was one of the 麻薬s used to 扱う／治療する U.S. 大統領 Donald Trump's coronavirus 感染, and has been shown in previous 熟考する／考慮するs to have 削減（する） time to 回復, though the European Union is 調査／捜査するing it for possible 腎臓 傷害.
The 世界保健機構 裁判，公判 was 行為／行うd in 11,266 adult 患者s in more than 30 countries. The 証拠 was conclusive, the 世界保健機構 said.
Gilead said other 裁判，公判s of remdesivir, 含むing with 1,062 患者s that compared it with a placebo, showed the 治療 削減（する） COVID-19 回復 time.
"The 現れるing (世界保健機構) data appears inconsistent, with more 強健な 証拠 from 多重の randomized, controlled 熟考する／考慮するs published in peer-reviewed 定期刊行物s 実証するing the 臨床の 利益 of remdesivir," Gilead told Reuters.
Gilead said it was "不明瞭な if any conclusive findings can be drawn" given what it called differences in how the 裁判，公判 was 行為／行うd from 場所／位置 to 場所／位置 and between the 患者s who received the 薬／医学.
In April, the 最高の，を越す U.S. 感染性の 病気 公式の／役人, Anthony Fauci, 予報するd remdesivir would become "the 基準 of care".
Companies such as Gilead are racing to find a 治療 for COVID-19. Some 1.1 million people have died and 39.1 million have been 報告（する）／憶測d 感染させるd in t he pandemic, and the 全世界の economy has been thrown into 大混乱.
Remdesivir was developed for Ebola, which 原因（となる）s fever, bleeding, vomiting and diarrhoea and spreads の中で humans through bodily fluids.
It was quickly repurposed and has 申し込む／申し出d some hope for 患者s, though the 世界保健機構's findings may 転換 the 焦点（を合わせる） of the search for a ワクチン to new monoclonal antibodies 存在 developed by companies 含むing Regeneron.
The 団結 裁判，公判 also 評価するd hydroxychloroquine, anti-HIV 麻薬 combination lopinavir/ritonavir and インターフェロン, and 結論するd that they, like remdesivir, did little to help 患者s 生き残る or leave the hospital more quickly.
The 世界保健機構 裁判，公判's results are yet to be reviewed and were uploaded on the preprint server medRxiv. (https://bit.ly/3nViYIf)
"PREMATURE"
Gilead say the 団結 結論s, 欠如（する）ing scrutiny from other scientists, were premature. "We are 関心d the data from this open-label 全世界の 裁判，公判 has not undergone the rigorous review 要求するd to 許す for 建設的な 科学の discussion, 特に given the 制限s of the 裁判，公判 design," it said.
Remdesivir got 緊急 use authorization from the U.S. Food and 麻薬 行政 on May 1, and has been 権限を与えるd for use in several countries.
During the 団結 熟考する／考慮する, 裁判，公判s of hydroxychloroquine and lopinavir/ritonavir were stopped in June after they 証明するd 効果のない／無能な, but the 熟考する／考慮するs of Gilead's 麻薬 and インターフェロン continued in more than 500 hospitals and 30 countries.
世界保健機構 長，指導者 scientist Soumya Swaminathan said this week the U.N. health 機関 was now looking at other, 現れるing 治療 選択s such as monoclonal anti-団体／死体s, immunomodulators and some newer anti-viral 麻薬s.
Regeneron 製薬のs Inc is developing a monoclonal antibody that Trump received for his COVID-19 感染.
Eli Lilly and Co said on Tuesday a 裁判，公判 of its COVID-19 antibody 治療 had been paused by the U.S. 政府 because of a safety 関心. (Reportin g by Vishwadha Chander, Deena Beasley, Stephanie Ulmer-Nebehay and John Miller in Switzerland, Ludwig Burger in Frankfurt; Editing by Shinjini Ganguli, Devika Syamnath and Timothy 遺産)
